We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor PR Newswire TAMPA, Fla. and SAN DIEGO, July 8, 2024...
Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones PR Newswire SAN DIEGO, July 1, 2024 SAN DIEGO, July 1...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.6 | -1.51802656546 | 105.4 | 105.6 | 102.2 | 1551773 | 103.20479805 | DE |
4 | -2 | -1.89035916824 | 105.8 | 106.8 | 102.2 | 1628818 | 104.63682995 | DE |
12 | 1.6 | 1.56555772994 | 102.2 | 106.8 | 101.4 | 2019723 | 103.53760971 | DE |
26 | -4.2 | -3.88888888889 | 108 | 108 | 101.4 | 1847013 | 104.03359493 | DE |
52 | 4.3 | 4.3216080402 | 99.5 | 108.8 | 94.4 | 1521309 | 102.66440625 | DE |
156 | -7.2 | -6.48648648649 | 111 | 117 | 94 | 1325374 | 103.24611199 | DE |
260 | -7.7 | -6.90582959641 | 111.5 | 117 | 74.2 | 1132198 | 103.60087712 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions